Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
A combination therapy using Claudin 18.2-targeting antibodies and γδ T cell stimulants like zoledronic acid and interleukin-2 enhances tumor control and survival in gastric and esophageal adenocarcinomas, addressing the limitations of current treatments.
Patent Information
- Application Number
- AU2026204800
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-06-22
- Publication Date
- 2026-07-09
AI Technical Summary
Current treatments for gastric and esophageal cancers, particularly adenocarcinomas, have limited efficacy and significant side effects, with median progression-free and overall survival rates of 5-7 months and 9-11 months, respectively, and targeted therapies like Trastuzumab are only effective in a small subset of patients.
A combination therapy involving an antibody (IMAB362) that binds specifically to Claudin 18.2, a tight junction protein overexpressed in cancer cells, combined with agents that stabilize Claudin 18.2 expression and stimulate γδ T cells, such as zoledronic acid and interleukin-2, to enhance tumor cell killing and immune response.
The combination therapy demonstrates enhanced tumor control and survival benefits in preclinical models, with improved efficacy against a range of cancer types, including gastric, esophageal, pancreatic, and lung adenocarcinomas, and reduces toxicity compared to single-agent treatments.